Results from this study could support an extension of the current approval of MVA-BN to include children from 2 years of age ...
The registrational trial is expected to support the approval for Bavarian’s mpox/smallpox vaccine use in children between two ...
adopting the recent approval from the European Medicines Agency (EMA) for this age group. Paul Chaplin, President & CEO of Bavarian Nordic, said: "Children remain highly vulnerable to mpox ...
adopting the recent approval from the European Medicines Agency (EMA) for this age group. Paul Chaplin, President & CEO of Bavarian Nordic, said: “Children remain highly vulnerable to mpox ...
Bavarian Nordic won an European Medicines Agency (EMA) approval for MVA-BN’s use in adolescents in September this year, whilst in the US it is still only approved in adults under the brand name ...